Stock Promoter Performance
Last 3 Stock Promotions By "OTC Stock Review"
|EHVVF||Ehave Inc.||July 22, 2020||0.150||-10%|
|RTSL||Rapid Therapeutic Science Laboratories, Inc.||June 22, 2020||0.450||0%|
|CANB||CAN B CORP.||November 21, 2019||0.017||0%|
EHVVF Promotional Newsletter
The following is a newsletter released by "OTC Stock Review" promoting Ehave Inc.
Just a quick pick late in the day. Ehave has been one of our clients for years and they seem to really be making a showing in both the Telemedicine and the Psychedelic Medicine Industry. The stock reversed 100 for 1 in May 2019 and traded up over $1 on light volume earlier this year. It's had some big days and was recently in the mid $0.40 range. The stock was trading around the $0.10$0.12 range, but it got whacked recently.
It seems a group purchased some restricted shares in return for some financing. Instead of taking their time getting out of some, they just pounded the stock. Ehave is a very proactive little company, and they do a lot of press releases.
The stock is $0.023 to $0.025. I think it's worth a look here, especially if you like looking for oversold low priced stocks.
Ehave, Inc. OTC EHVVF planted its feet smack dab in the middle of the Psychedelic Medicine industry by acquiring PsychedeliTech, a division of Israel based Israel Cannabis Limited iCAN. PsychedeliTech is the parent of PsyTech, which had originally planned to host an inaugural PsyTech Summit last March at the Hilton Hotel, on the Mediterranean Sea in Tel Aviv, Israel. The event was cancelled as a result of the Covid 19 pandemic, but Ehave and PsyTech have hosted a successful series of PsyTech Virtual Summits, which have been held online.
These Psychedelic Industry Webinars have featured distinguished players in the Psychedelic Medicine industry such as Rick Doblin, Executive Director of Multidisciplinary Association for Psychedelic Studies MAPS Todd Shapiro, CEO of Red Light Holland Bruce Linton, Founder and Former Chairman and Co-CEO of Canopy Growth Saul Kaye, Founder CEO, can Israel Cannabis Shlomi Raz, ChairmanFounder, Eleusis JR Rahn, Co-FounderDirector, MindMed Matthew Johnson, PhD., Professor of Psychiatry and Behavior, Johns Hopkins Tyler Bryden, Founder Speak Ai Sessions Sarah Hashkes, CEO of Radix Motion Christian Angermayer, Founder, ATAI Life Sciences Dr. Rosalid Watts, Clinical Psychologist at the Psychedelic Research Group at Imperial College London and James Stephens, Chief Science Office and Co-Founder of Aurelius Data.
The next webinar presented by Ehave and PsyTech will be July 29, 2020 at 1200 PM Eastern Time. The webinar is titled Mystical Experience, Religion, and Psychedelics. Interested investors can sign up here for free
The company believes that its Dash platform will play a crucial role in the global advancement of psychedelic research. As a HIPAA and GDPR compliant platform, Dash is secure and compliant with some of the world's strictest privacy laws. It's an optimal way to compile psychedelic research and results to provide easy access for scientists globally. Ehave recently acquired 51% of MDLink, a Jamaican Telemedicine provider. MDLink is licensed for all CARICOM Countries which include Antigua and Barbuda, Belize, Dominica, Grenada, Guyana, Haiti, Jamaica, Montserrat, Saint Kitts, Nevis, Saint Lucia, Saint Vincent, Rhe Grenadines, Suriname and Trinidad and Tobago. MDLink currently has over 10,000 patients. Ehave plans to develop a platform for MDLink Mental Health Therapy. Additionally, MDLink has entered into a technical cooperation agreement with the Inter-American Development Bank IDB Lab to design and test a digital screening solution for COVID-19 on the MDLink platform. The digital screening solution will allow vulnerable patients, such as those with pre-existing conditions and the elderly, to connect virtually from their homes with licensed physicians.
Psychedelics are quickly picking up steam among both researchers and investors. As the market opens up, forward-thinking companies are building an early presence in the space before it grows into a large and mainstream industry. Micro Cap investors may want to consider building a position in some of these companies given the similarities. There is an uptrend in the research of psychedelic substances for treating mental illnesses like addiction, depression, anxiety and posttraumatic stress disorder PTSD. Researchers at Johns Hopkins University and the Multidisciplinary Association for Psychedelic Studies MAPS are pioneering research on psychedelic medicine, while the Yale Psychedelic Science Group is initially focused on contemporary clinical research and the mechanisms of action of psychedelic treatments. Both Forbes and CNN noticed the trend and recently published articles on the resurgence of research into psychedelics. As these researchers open new doors for the treatment of mental health issues, there exists a world of opportunity for the commercialization of research into psychedelics.
The big difference between psychedelic medicine and cannabis is the way in which they're used in therapy. Psilocybin is used to enhance therapy and is not necessarily the treatment while cannabis mostly treats symptoms. The U.S. Food and Drug Administration FDA authorized Breakthrough Therapy Designation to both Compass Pathways' and Usona Institute's psilocybin therapy for depression in 2018. Johnson Johnson's NYSE JNJ ketamine-derived medicine, Spravato, has been available for pain relief for years. In March 2019, the FDA approved Spravato for treatment-resistant depression. This was huge, since ketamine not only has hallucinogenic properties, but is well known as a party drug by its common street names K, Special K, Kit Kat, and Jet, as well as a few others. Last September a group of private donors ponied up $17 million to start the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, making it what's believed to be the first such research center in the U.S. and the largest research center of its kind in the world. Just as we saw with cannabis, voters in cities like Denver, Oakland, and Santa Cruz voted to decriminalize magic mushrooms.
OTC Symbol EHVVF
Current Price $0.023 x $0.025
Shares Outstanding 29 million
Market Cap $4.25 million
52 Week Trading Range
52-Week Low $0.013
52-Week High $1.10
18851 NE 29th Ave., Suite 700
Aventura, FL 33180
Phone 954 233-3511
DISCLAIMER Atlanta Capital Partners, LLC ATLCP, which owns and operates Otcstockreview.com, is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. ATLCP is NOT affiliated in any manner with any company mentioned herein. ATLCP and its affiliated companies are news dissemination solutions providers and are not a registered brokerdealeranalystadviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. ATLCP's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is never to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. ATLCP is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed ATLCP was compensated one thousand five hundred dollars for news coverage of current press releases issued by Ehave, Inc. by a non-affiliated third party. ATLCP holds no shares of any company named in this release.
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results, or strategies and are generally preceded by words such as may, future, plan or planned, will or should, expected, anticipates, draft, eventually or projected. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and ATLCP undertakes no obligation to update such statements.
If you no longer wish to receive these emails, please reply to this message with Unsubscribe in the subject line or simply click on the following link
to forward this email to a friend
OTC Stock Review
235 Peachtree St. NE
Atlanta, Georgia 30303
the marketing policy.
Get Every Penny Stock Alert!
OTC Dynamics tracks all penny stock promotions. Become a member today and never miss another penny stock promotion!
OTC Dynamics is not affiliated with the company being promoted or the associated stock promoter.
The information on this page is not a recommendation to buy or sell securities.